Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(14%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
2
29%
Ph phase_1
4
57%
Ph phase_2
1
14%

Phase Distribution

4

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
4(57.1%)
Phase 2Efficacy & side effects
1(14.3%)
Phase 3Large-scale testing
2(28.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(1)
Completed(3)
Terminated(1)
Other(2)

Detailed Status

Completed3
unknown2
Withdrawn1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (57.1%)
Phase 21 (14.3%)
Phase 32 (28.6%)

Trials by Status

unknown229%
withdrawn114%
active_not_recruiting114%
completed343%

Recent Activity

1 active trials
Showing 5 of 7
active_not_recruitingphase_1

Autologous Dendritic Cell as Adjunct Therapy for Diabetic Kidney Disease

NCT06866158
completedphase_1

MIDRIXNEO-LUNG Dendritic Cell Vaccine in Patients With Non-small Cell Lung Cancer

NCT04078269
unknownphase_3

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

NCT00045968
unknownphase_1

MIDRIX4-LUNG Dendritic Cell Vaccine in Patients With Metastatic Non-small Cell Lung Cancer

NCT04082182
completedphase_2

Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors

NCT00576537
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT06866158Phase 1

Autologous Dendritic Cell as Adjunct Therapy for Diabetic Kidney Disease

Active Not Recruiting
NCT04078269Phase 1

MIDRIXNEO-LUNG Dendritic Cell Vaccine in Patients With Non-small Cell Lung Cancer

Completed
NCT00045968Phase 3

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

Unknown
NCT04082182Phase 1

MIDRIX4-LUNG Dendritic Cell Vaccine in Patients With Metastatic Non-small Cell Lung Cancer

Unknown
NCT00576537Phase 2

Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors

Completed
NCT00043212Phase 3

Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.

Withdrawn
NCT00547144Phase 1

Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer

Completed

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7